News & Updates
Showing Oncology articles
Showing

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Repeat transurethral resection of bladder tumour predicts but does not improve survival
Repeat transurethral resection of bladder tumour prior to radical cystectomy, regardless of whether or not neoadjuvant chemotherapy is administered, does not seem to improve survival in patients with muscle-invasive bladder cancer, reveals a recent study.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Postoperative neutropaenia tied to early CRBSI in children with leukaemia
Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.


